ROC curves in the discovery cohort, and NRM using the thresholds in the discovery cohort. (A) ROC curves of the 3 candidate biomarkers at day +180 for the prediction of NRM in the discovery cohort. ROC curves were used to define the thresholds of biomarkers for NRM by minimizing the distance from the upper left corner of the graph. The thresholds of GAL3, M2BP, and M2BPGi were 18, 70, and 1.5, and AUCs were 0.64, 0.75, and 0.91, respectively. (B) NRM in the discovery cohort, validation cohort 1, and validation cohort 2 stratified by M2BPGi at day +180 using the cutoff in the discovery cohort (thresholds of COI values: 1.5). NRM at 5 years from sample collection in the discovery cohort was 23.3% (95% CI, 8.0-43.2) for the group with higher M2BPGi and 0.0% (95% CI, 0.0-0.0) for the group with lower M2BPGi (P = .001). NRM at 5 years from sample collection in validation cohort 1 was 34.0% (95% CI, 15.7-53.3) for the group with higher M2BPGi and 8.4% (95% CI, 1.3-24.5) for the group with lower M2BPGi (P = .014). NRM at 2 years from sample collection in validation cohort 2 was 35.3% (95% CI, 8.4-64.5) for the group with higher M2BPGi and 4.0% (95% CI, 0.3-17.4) for the group with lower M2BPGi (P = .045). (C) ROC curve of M2BPGi at day +180 for the prediction of NRM in validation cohort 1 (AUC for M2BPGi, 0.82). (D) ROC curves for total bilirubin (left panel) and ALT (right panel) at day +180 for the prediction of NRM in the entire cohort (AUC for total bilirubin, 0.51; AUC for ALT, 0.49).